HLB's liver cancer drug rivoceranib has again failed to clear the US Food and Drug Administration, receiving a complete response letter for the third time.

On July 15, HLB announced that the general cGMP inspection for the active pharmaceutical ingredient (API) manufacturing facility, which had been cited ...

The government has been rolling out policies to revitalize the KOSDAQ market one after another, but the money flow that ...

The FBM KLCI slipped below the 1,700 psychological level during intraday trade on Friday before recovering to close above the mark, tracking a broad regional sell-off ...

Florida’s once thriving citrus industry has declined precipitously over the past two decades, but state agriculture officials believe the downward trajectory may have plateaued, and expressed ...

Bursa Malaysia closed lower across the board on Friday, as investors assessed the impact of the United States’ latest tariffs ...

Turnover narrowed to 3.03 billion units valued at RM2.3 billion from 3.19 billion units valued at RM2.27 billion yesterday.

Prosys Tech Corporation (“Prosys ” or the “Corporation ”) is pleased to announce the signing of a letter of intent with Aeronautics Fund SCA SICAV-RAIF (“AFD ”) and certain of its registered fund ...

Following yesterday's (the 28th) plunge, the Kospi slid nearly 6% today (the 29th), falling below the 6,000 threshold. Amid ...

The preview of Lentor Gardens Residences, which drew 5,000 people, and saw 54% of units sold at launch (Photo: Kingsford ...